Table 4 Summary of Treatments to Increase Exogenous Uptake of FITC-Subtilisin
Treatment | Uptake and Processing | |
|---|---|---|
1. | Active Subtilisin | Cell Lysis |
2. | TCA-precipitated FITC-subtilisin | Uptake, no increase in processing |
3. | Autolysed FITC-subtilisin | Uptake, no increase in processing |
4. | FITC-subtilisin antibody conjugate | Uptake, no increase in processing |
5. | FITC-subtilisin crosslinked with glutaraldehyde | Uptake, no increase in processing |
6. | Carriers (BioPorter, Chariot, TAT peptide) + FITC-subtilisin | Uptake, no increase in processing |
7. | Liposomes + FITC-subtilisin | Uptake, no increase in processing |
8. | Alpha-2-macroglobulin + FITC-subtilisin | No increase |
9. | IFN gamma + FITC-subtilisin | 10–25% increase in processing |
10. | Pulse 2 hr, 12 hr, 24 hr, 36 hr, 48 hr | 24 hr best |
11. | Antigen dose 100–900 μg/mL | 100–200 μg/mL best |